This app uses Apple Intelligence to generate custom images on your device. You can choose from a list of suggested prompts, or you can enter your own description of an image and your iPhone will ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer. The agent improved PFS but not OS vs. investigator’s choice of chemotherapy.

The drug, known as datopotamab deruxtecan but marketed under the brand name Datroway, is intended to treat hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2 ...

Tokyo: D aichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate. This approval marks a significant ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...

The drug, known in development as datopotamab deruxtecan, or Dato-DXd, will be marketed under the brand name Datroway. Datroway is part of a class of therapies called antibody drug conjugates ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...

Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form of breast cancer last month, its first regulatory green light. The U.S. list price for Datroway is ...

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

The FDA has greenlighted the drug, datopotamab deruxtecan, for HR-positive, HER2-negative breast cancer in patients who have tried prior endocrine-based therapy and chemotherapy. The TROP2 ...

Datopotamab deruxtecan-dlnk significantly improves progression-free survival in HR-positive, HER2-negative breast cancer compared with chemotherapy. The TROPION-Breast01 trial showed a higher ...